4/15
01:12 pm
fdmt
Rating for FDMT
Low
Report
Rating for FDMT
4/15
01:12 pm
fdmt
Rating for FDMT
Low
Report
Rating for FDMT
4/15
08:11 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $45.00 price target on the stock.
Low
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $45.00 price target on the stock.
4/15
07:05 am
fdmt
Rating for FDMT
Low
Report
Rating for FDMT
4/15
07:05 am
fdmt
Rating for FDMT
Low
Report
Rating for FDMT
4/1
12:16 pm
fdmt
Rating for FDMT
Medium
Report
Rating for FDMT
4/1
12:16 pm
fdmt
Rating for FDMT
Medium
Report
Rating for FDMT
4/1
10:48 am
fdmt
Rating for FDMT
Low
Report
Rating for FDMT
4/1
10:48 am
fdmt
Rating for FDMT
Low
Report
Rating for FDMT
3/1
08:13 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
Low
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
2/7
07:16 am
fdmt
Rating for FDMT
High
Report
Rating for FDMT
2/7
07:16 am
fdmt
Rating for FDMT
High
Report
Rating for FDMT
2/7
07:16 am
fdmt
Rating for FDMT
High
Report
Rating for FDMT
2/5
12:39 pm
fdmt
Rating for FDMT
Medium
Report
Rating for FDMT
2/5
12:39 pm
fdmt
Rating for FDMT
Medium
Report
Rating for FDMT
2/5
09:54 am
fdmt
Rating for FDMT
Medium
Report
Rating for FDMT
2/5
09:54 am
fdmt
Rating for FDMT
Medium
Report
Rating for FDMT
1/29
01:10 pm
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $25.00 price target on the stock.
Low
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $25.00 price target on the stock.
1/29
01:10 pm
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $25.00 price target on the stock.
Low
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $25.00 price target on the stock.
1/29
12:09 pm
fdmt
Rating for FDMT
Low
Report
Rating for FDMT
1/29
12:09 pm
fdmt
Rating for FDMT
Low
Report
Rating for FDMT